BRIEF-ImmunityBio’s ANKTIVA® Improves Survival in Advanced NSCLC by Reversing Lymphopenia

Reuters09-08

Sept 8 (Reuters) - Immunitybio Inc IBRX.O:

IMMUNITYBIO’S ANKTIVA® REVERSES LYMPHOPENIA AND EXTENDS OVERALL SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER RESISTANT TO CHECKPOINT THERAPY

Source text: ID:nBw5Mzl2la

Further company coverage: IBRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2565814686?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 20:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565814686","market":"nz","top_or_hot":-1,"title":"BRIEF-ImmunityBio’s ANKTIVA® Improves Survival in Advanced NSCLC by Reversing Lymphopenia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-ImmunityBio’s ANKTIVA® Improves Survival in Advanced NSCLC by Reversing Lymphopenia</title></head><body><p><span>Sept 8 (Reuters)</span><span> - </span>Immunitybio Inc <span>IBRX.O</span>:</p><ul><li><p>IMMUNITYBIO’S ANKTIVA® REVERSES LYMPHOPENIA AND EXTENDS OVERALL SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER RESISTANT TO CHECKPOINT THERAPY</p></li></ul><p>Source text: <span>ID:nBw5Mzl2la</span></p><p>Further company coverage: <span>IBRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-ImmunityBio’s ANKTIVA® Improves Survival in Advanced NSCLC by Reversing Lymphopenia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-ImmunityBio’s ANKTIVA® Improves Survival in Advanced NSCLC by Reversing Lymphopenia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-08 20:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-ImmunityBio’s ANKTIVA® Improves Survival in Advanced NSCLC by Reversing Lymphopenia</title></head><body><p><span>Sept 8 (Reuters)</span><span> - </span>Immunitybio Inc <span>IBRX.O</span>:</p><ul><li><p>IMMUNITYBIO’S ANKTIVA® REVERSES LYMPHOPENIA AND EXTENDS OVERALL SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER RESISTANT TO CHECKPOINT THERAPY</p></li></ul><p>Source text: <span>ID:nBw5Mzl2la</span></p><p>Further company coverage: <span>IBRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nFWN3UV0LU:1","article_id":"2565814686","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565814686","pubTimestamp":1757335533,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-ImmunityBio’s ANKTIVA Improves Survival in Advanced NSCLC by Reversing LymphopeniaSept 8 (Reuters) - Immunitybio Inc IBRX.O:IMMUNITYBIO’S ANKTIVA REVERSES LYMPHOPENIA AND EXTENDS OVERALL SURVIVA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc.","BK4139":"生物科技"},"translate_title":"简介-ImmunityBio的ANKTIVA®通过逆转淋巴细胞减少症提高晚期非小细胞肺癌的生存率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"BRIEF-ImmunityBio’s ANKTIVA® Improves Survival in Advanced NSCLC by Reversing LymphopeniaSept 8 (Reuters) - Immunitybio Inc IBRX.O:IMMUNITYBIO’S ANKTIVA® REVERSES LYMPHOPENIA AND EXTENDS OVERALL SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER RESISTANT TO CHECKPOINT THERAPYSource text: ID:nBw5Mzl2laFurther company coverage: IBRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2565814686","isCrawlerRequest":true}